A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Listed as NCT00620555, this PHASE3 trial focuses on Epilepsies, Partial and remains completed. Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Hiroshima, Japan , Izumi-shi, Japan , Jonan-ku, Japan , Kanazawa, Japan , Kobe, Japan , Kodaira, Japan , Kurashiki, Japan , Miyakojima-ku, Japan , Niigata, Japan , Obu-shi,Morioka-machi, Japan and 12 more locations